{"id":499532,"date":"2026-06-14T17:25:07","date_gmt":"2026-06-14T17:25:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/499532\/"},"modified":"2026-06-14T17:25:07","modified_gmt":"2026-06-14T17:25:07","slug":"study-reveals-frequent-stop-and-start-patterns-with-glp-1-drugs","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/499532\/","title":{"rendered":"Study reveals frequent stop-and-start patterns with GLP-1 drugs"},"content":{"rendered":"<p>People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society&#8217;s annual meeting in Chicago, Ill.<\/p>\n<p>&#13;<\/p>\n<p>Our study asked two questions that haven&#8217;t been well answered until now: How many <a href=\"https:\/\/www.news-medical.net\/health\/What-is-Type-2-Diabetes.aspx\" class=\"linked-term\" rel=\"nofollow noopener\" target=\"_blank\">people with type 2 diabetes<\/a> taking GLP-1 medications actually stop using them? And how many restart them?&#8221;<\/p>\n<p>&#13;<br \/>\n&#13;<\/p>\n<p style=\"text-align: right;\">Sainikhil Sontha, M.S., research associate, Boston University School of Public Health, Boston, Mass.<\/p>\n<p>&#13;<\/p>\n<p>The researchers performed a retrospective cohort study using Komodo Health U.S. claims data (January 2019 to June 2025). The group included adults aged 18 to 64 years with a BMI \u226525 kg\/m\u00b2 and type 2 diabetes who started liraglutide, semaglutide, or tirzepatide, and had previously enrolled within the last year with more than 6 months of follow-up.<\/p>\n<p>Discontinuation was defined as having more than a 60-day gap in filling their GLP-1 prescriptions. Getting a new fill after discontinuation was considered as reinitiation.<\/p>\n<p>&#8220;Using insurance records from more than 60,000 Americans with type 2 diabetes, we found that about 4 in 10 patients stopped their GLP-1 medication within the first year, and nearly 6 in 10 had stopped by the end of two years,&#8221; Sontha said.<\/p>\n<p>But they also found something encouraging.<\/p>\n<p>&#8220;More than half of those who stopped restarted therapy within a year (41.5%), and nearly two-thirds did so within two years (58%),&#8221; Sontha said. &#8220;This suggests that for many patients, these medications aren&#8217;t being abandoned permanently; use is more start-and-stop than most people assumed.&#8221;<\/p>\n<p>Using Cox proportional hazards models, they also took sociodemographic, clinical and provider-level predictors into consideration.<\/p>\n<p>Sontha and colleagues found that those on Medicaid or Medicare, Black patients, and those experiencing nausea or other stomach-related side effects (37%) were more likely to discontinue a GLP-1 medication within a year.<\/p>\n<p>People were 10% less likely to stop if their first GLP-1 medication was prescribed by an endocrinologist.<\/p>\n<p>What&#8217;s more, people taking newer medications like tirzepatide were 41% less likely to discontinue than those taking older drugs like liraglutide. Semaglutide users were 28% less likely to discontinue anti-obesity medication use than those taking older medications.<\/p>\n<p>&#8220;This research matters because consistent use of these medications is what produces their protective effects,&#8221; Sontha said. &#8220;Stopping early may mean missed opportunities to prevent heart attacks, kidney disease progression and other complications.&#8221;<\/p>\n<p>The researchers hope that these findings give providers, insurers and policymakers an idea of which patients need more support to stay on GLP-1 medications, he said.<\/p>\n","protected":false},"excerpt":{"rendered":"People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being&hellip;\n","protected":false},"author":2,"featured_media":343500,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[1702,56129,103,9385,61,60,4369,2361,89,10421,9398],"class_list":["post-499532","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-diabetes","tag-endocrine","tag-health","tag-hormone","tag-ie","tag-ireland","tag-obesity","tag-public-health","tag-research","tag-semaglutide","tag-type-2-diabetes"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/499532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=499532"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/499532\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/343500"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=499532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=499532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=499532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}